New Delhi [India], Amid reports of possible rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which has developed Covaxin, said in a statement that the vaccine will be developed "with a focus on safety first." "Together" will be developed. It said Covaxin was the "only Covid vaccine" in the Indian government's COVID-19 vaccination program that had been tested for efficacy in India. Notably, Covishield and Covaxin were the vaccines primarily administered during the Covid pandemic, Bharat Biotech said in its statement, adding that Covaxin was evaluated in over 27,000 subjects. Under the process, it was licensed for unrestricted use in clinical trial mode, where detailed safety reporting was conducted for several lakh subjects. The safety of Covaxin was also evaluated with ongoing safety monitoring (pharmacovigilance) by the Ministry of Health, Government of India.) operated. This continued throughout the product life cycle of Covaxin. All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin, with no vaccine-related events such as blood clots, thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc. It further added, “As seasoned innovators and product developers, the Bharat Biotech team knew well that, although the efficacy of COVID-19 vaccines may be short-lived, the impact on patient safety can be life-long. “Safety is therefore the primary focus for all of our vaccines,” the statement said.''This comes in the wake of the recent admission by pharmaceutical company AstraZeneca that its Covid vaccines Covishield and Vaxzevria ''can, in very rare cases, cause thrombocytopenia syndrome. Could be the reason(TTS). AstraZeneca has admitted in court documents in connection with a case that the vaccine it developed with the University of Oxford caused dozens of deaths and serious injuries, according to multiple UK media reports. Following the report, an AstraZeneca spokesperson said, "Our sympathies go out to those who have lost loved ones or reported health problems. Patient safety is our top priority, and regulatory authorities have reviewed all medicines, including vaccines. Security has been ensured." Serum Institute of India has put in place strict standards to ensure its use.The COVID-19 vaccine is named Covishield, but it does not use the mRNA platform, it has been prepared using the viral vector platform. A chimpanzee adenovirus – ChAdOx1 – has been modified to be able to carry the COVID-19 spike protein into cells. This cold virus is basically incapable of infecting the receiver, but may well teach the immune system to prepare a mechanism against such viruses.